![clinicImage](https://img.bookimed.com/clinic_webp/605d9ea1621c6_b.webp)
Doctor Yesim Yildirim is an oncologist certified by the European Society of Medical Oncology (ESMO). Affiliated with numerous hospitals in the United States and Turkey, including the University of Maryland Medical Center, Johns Hopkins Hospital and Memorial Sisli Hospital. She has over 20 years of experience and has a special interest in preventive medicine, diabetes, and hypertension. Holds an MBA in Healthcare Management and shares her expertise with Bookimed from 2022.
The Medical Advisory Board expert is a verified credible medical professional with solid theoretical background and practical experience in the field. The expert provides support related to medical content accuracy for medical writers and performs educational workshops to Bookimed coordinators serving patient requests.
The medical content creation under the expert’s control follows rigorous and well-established procedure to be informative, trustworthy, and transparent and making Bookimed.com a credible source of evidence-based health information.
Transfer airport-clinic-airport
Personal medical coordinator
Medical travel arrangements — booking of air tickets and hotel rooms at special partner prices
Patient advocacy during medical travel
Pembrolizumab belongs to the group of the immunotherapy drugs — type of medicine that can treat certain cancers by influencing on patient's immune system. It blocks a protective mechanism of cancer cells and allows the immune system to destroy them. Monoclonal antibody to programmed cell death-1 protein (PD-1) blocks the interaction between PD-1 and its ligands — PD-L1 and PD-L2.
Keytruda prices are specified in this listing. Submit a request to get a personalized quote.
On May 23, 2017, the U.S. Food and Drug Administration granted for Pembrolizumab (Keytruda) an accelerated approval — faster approval of drugs for serious conditions that fill an unmet medical need. FDA allowed prescribing immunotherapy new drug to treat patients whose cancers have a specific genetic feature (biomarker).
During the clinical trials of Keytruda, the following indicators were achieved:
Period |
The survival rate of patients with 3-4 stages of cancer |
6 month |
92% |
1 year |
69% |
1,5 years |
62% |
2 years |
58% |
The manufacturer is Merck & Co., Inc. — an American pharmaceutical company and one of the largest pharmaceutical companies in the world. Research performed at Merck has led to FDA approval of 63 new drugs. Company has developed more new drugs than any other company in the USA.